Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022
InfectologiaSobre o estudo
- Desenho
- Diretriz clínica
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- MMWR. Morbidity and mortality weekly report
- Publicado em
- 25 fev 2022
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022
Wendy Carr, Ekaterina Kurbatova, Angela Starks, Neela Goswami, Leeanna Allen, Carla Winston
Descritores MeSH
- Moxifloxacin
- Antitubercular Agents
- Isoniazid
- Pyrazinamide
- Rifampin
- Tuberculosis, Pulmonary
- United States
- Randomized Controlled Trials as Topic
- Centers for Disease Control and Prevention, U.S.
- Drug Administration Schedule
Veja também
Estudos relacionados
- Rifapentine dosing for drug-susceptible tuberculosis: stage 1 of a seamless phase 2/3 randomized clinical trial
- Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trial
- Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial
- Treatment Strategy for Rifampin-Susceptible Tuberculosis